Video Series

Immune checkpoint inhibitors can play a key role in the treatment of upper-GI and esophageal cancer.

Key opinion leaders navigate unmet needs across the treatment landscape of gastroesophageal cancer.

Managed care experts discuss health disparities among various patient populations affected by MDD.

Drs Cannon and Rothrock provide insights into their process for defining value among newly launched MDD treatments.

Experts from US Oncology, Tennessee Oncology, AON, and COA dig into the details of implementing the Enhancing Oncology Model, set to take effect July 1, 2023.

Medical experts illustrate characteristics in the presentation of lupus nephritis.

Alvin Wells, MD, PhD, opens a discussion surrounding systemic lupus erythematosus (SLE) and lupus nephritis (LN).

Key opinion leaders provide their final thoughts on treatment management for patients with MDS.

The expert panel looks to future treatment management for patients with myelodysplastic syndrome.

Laura Bobolts, PharmD, BCOP, discusses key cost drivers impacting treatments for upper GI and esophageal cancers.

Laura Bobolts, PharmD, BCOP, and James M. Cleary, MD, PhD, explore the evolution of treatment for patients with upper GI and esophageal cancer, including first- and second-line treatment strategies for gastroesophageal cancer.

Panelists provide their key considerations when determining appropriate treatment options for patients with major depressive disorder.

Key opinion leaders discuss the importance of early effective treatment for patients with MDD.

Dr Siefker-Radtke provides her closing thoughts on her takeaways from ESMO 2022, including a study focusing on penpulimab plus anlotinib.

Disitamab vedotin is a promising antibody-drug conjugate option undergoing evaluation for patients with metastatic urothelial cancer.

Dr Siefker-Radtke shares takeaways from the SOGUG-AUREA study and its influence on treatment for patients with urothelial cancer.

Unmet needs in MDS treatment management are proposed by Salman Fazal, MD.

Dr Haumschild leads a discussion regarding cost-associated burden for patients with MDS.

Major depressive disorder treatment failure can lead to subsequent costs and poor outcomes, affecting payer considerations in the treatment landscape.

Consequences attributed to poorly controlled and recurrent MDD are evaluated by Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP.

The SOGUG-AUREA study explored overall survival of atezolizumab plus split-dose cisplatin-gemcitabine in patients with locally advanced and metastatic urothelial cancer.

Enfortumab vedotin monotherapy or its combination with pembrolizumab could significantly evolve the treatment landscape for urothelial cancer.

Drs Fazal and Zeidan illustrate the roles and challenges of implementing oral therapies in MDS treatment management.

Clinical pathways in MDS treatment are explored by Amer Zeidan, MBBS, MHS, and Jay Weaver, PharmD, MPH.

Expert panelists discuss the lack of diversity among available treatment options for MDD.

Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP, open a discussion surrounding payer considerations relating to the treatment of major depressive disorder (MDD).

Dr Siefker-Radtke explores unmet needs in the treatment of patients with urothelial cancer and how novel immunotherapies can address some of the challenges with traditional chemotherapy.

Key considerations for appropriate MDS treatment selection are discussed by expert panelists.

Salman Fazal, MD, shares opinions regarding the role of hypomethylating agents (HMAs) in treatment for patients with MDS.

Arlene Siefker-Radtke, MD, opens a discussion recapping the ESMO 2022 conference surrounding advanced and metastatic urothelial cancer.